Neuraminic acid is the core structure of most known sialic acids. In natural systems, the amino group at the 5 position of neuraminic acid residues is usually assumed to be acylated. Previously, synthetic de-N-acetyl-gangliosides (with free amino groups at the 5 position of neuraminic acids) have been shown to modulate cellular proliferation and tyrosine phosphokinase reactions. While indirect evidence has suggested that traces of these molecules exist naturally in certain tumor cells, further exploration has been hampered by the lack of a system showing consistent expression at an easily detectable level. Using synthetic compounds as antigens, we have developed highly specific monoclonal antibodies against de-N-acetyl-G and de-N-acetyl-G that require both the free amino group and the exocyclic side chain of sialic acids for recognition. Cultured human melanoma cells showed low but variably detectable levels of reactivity with these antibodies. The ability of various biologically active molecules to stimulate this reactivity was explored. Of many compounds tested, only the tyrosine kinase inhibitor genistein induced reactivity in a dose-dependent manner. Antibody reactivity with ganglioside extracts from genistein-treated cells was abolished by chemical re-N-acetylation and/or truncation of sialic acid side chains by mild periodate oxidation. High performance thin layer chromatography immuno-overlay analysis confirmed the presence of the novel compound de-N-acetyl-G in these extracts. Several other tyrosine kinase inhibitors tested did not give the same increase in de-N-acetyl-ganglioside expression. However, the microtubule inhibitor nocodazole caused a similar accumulation of these molecules, particularly in non-adherent cells expected to be arrested at metaphase. Thus, genistein may induce de-N-acetyl-ganglioside expression by virtue of its known ability to arrest cells in the GM phase, rather than as a general consequence of tyrosine kinase inhibition. These studies also provide a system in which to analyze the enzymatic basis of de-N-acetyl-ganglioside expression and their potential roles as growth regulating molecules.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				I. Popa, A. Pons, C. Mariller, T. Tai, J.-P. Zanetta, L. Thomas, and J. Portoukalian Purification and structural characterization of de-N-acetylated form of GD3 ganglioside present in human melanoma tumors Glycobiology, April 1, 2007; 17(4): 367 - 373. [Abstract] [Full Text] [PDF]

				J. L. Sonnenburg, H. van Halbeek, and A. Varki Characterization of the Acid Stability of Glycosidically Linked Neuraminic Acid. USE IN DETECTING DE-N-ACETYL-GANGLIOSIDES IN HUMAN MELANOMA J. Biol. Chem., May 10, 2002; 277(20): 17502 - 17510. [Abstract] [Full Text] [PDF]

				J.-P. Zanetta, A. Pons, M. Iwersen, C. Mariller, Y. Leroy, P. Timmerman, and R. Schauer Diversity of sialic acids revealed using gas chromatography/mass spectrometry of heptafluorobutyrate derivatives Glycobiology, August 1, 2001; 11(8): 663 - 676. [Abstract] [Full Text] [PDF]

				R. Chammas, J. L. Sonnenburg, N. E. Watson, T. Tai, M. G. Farquhar, N. M. Varki, and A. Varki De-N-acetyl-gangliosides in Humans: Unusual Subcellular Distribution of a Novel Tumor Antigen Cancer Res., March 1, 1999; 59(6): 1337 - 1346. [Abstract] [Full Text] [PDF]

				C. Mitsuoka, K. Ohmori, N. Kimura, A. Kanamori, S. Komba, H. Ishida, M. Kiso, and R. Kannagi Regulation of selectin binding activity by cyclization of sialic acid moiety of carbohydrate ligands on human leukocytes PNAS, February 16, 1999; 96(4): 1597 - 1602. [Abstract] [Full Text] [PDF]

				W.-X. Shi, R. Chammas, and A. Varki Regulation of Sialic Acid 9-O-Acetylation during the Growth and Differentiation of Murine Erythroleukemia Cells J. Biol. Chem., December 6, 1996; 271(49): 31517 - 31525. [Abstract] [Full Text] [PDF]